133040-02-5

Basic information

• Product Name: Benzoic acid, 4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-, methyl ester
• CAS NO: 133040-02-5
• Molecular Formula: C17H19ClN2O3
• Molecular Weight: 334.802
• Mol File: 133040-02-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-, methyl ester(133040-02-5)
• EPA Substance Registry System: Benzoic acid, 4-[(2-butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-, methyl ester(133040-02-5)

Safety Data

• Hazardous Substances Data: 133040-02-5(Hazardous Substances Data)

Upstream product

• 34040-64-7 p-methyloxycarbonylbenzyl chloride 
• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 68282-49-5 2-butyl-1H-imidazole-5-carboxaldehyde 
• 68283-19-2 2-butyl-5-hydroxymethyl-1H-imidazole 
• 110-59-8 pentanonitrile 
• 50790-93-7 2-butyl-1H-imidazole 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 

Downstream Products

• 133040-01-4 eprosartan 
• 133040-03-6 2-n-butyl-1-[(4-carbomethoxyphenyl)methyl]-1H-imidazol-5-carboxaldehyde 
• 148674-53-7 4-[2-Butyl-5-((E)-2-cyano-3-thiophen-2-yl-propenyl)-imidazol-1-ylmethyl]-benzoic acid methyl ester 
• 148674-39-9 SB 206328 
• 135123-85-2 4-[5-((E)-2-tert-Butoxycarbonyl-3-thiophen-2-yl-propenyl)-2-butyl-imidazol-1-ylmethyl]-benzoic acid methyl ester 
• 148674-45-7 (E)-3-<2-butyl-1-<(4-carbomethoxyphenyl)methyl>imidazol-5-yl>-2-(2-thienylmethyl)-2-propenamide 
• 133486-01-8 (E)-3-<2-butyl-1-<(4-carbomethoxyphenyl)methyl>imidazol-5-yl>-2-(2-thienylmethyl)-2-propenoic acid 
• 133486-07-4 (E)-3-<2-butyl-1-<(4-carboxamidophenyl)methyl>imidazol-5-yl>-2-(2-thienylmethyl)-2-propenamide 
• 148674-52-6 4-[2-Butyl-5-((E)-2-cyano-3-thiophen-2-yl-propenyl)-imidazol-1-ylmethyl]-benzonitrile 

Relevant articles and documents

Eprosartan intermediate of a kind of improved process for preparing aryl imidazole aldehyde

The invention discloses an improved process for preparing aryl imidazole aldehyde serving as an eprosartan intermediate. The process comprises the following steps of: performing methyl esterification reaction on parachloro-methylbenzoic acid to obtain parachloro-methyl benzoate; reacting the parachloro-methyl benzoate and imidazole aldehyde under agitation by taking dimethyl formamide (DMF) as a reaction solvent and potassium carbonate as an alkali at the temperature of between 20 and 40 DEG C; after reaction, filtering to remove the potassium carbonate; adding water into filtrate under agitation for crystallizing; and recovering the aryl imidazole aldehyde serving as the eprosartan intermediate. The process has the advantages of high yield, high purity of products, relatively low content of N-heterogeneous impurities, extremely low content of dimeric impurities and the like, can be used in the next process without refining, and is suitable for large-scale industrial production.

IMPROVED PROCESS FOR EPROSARTAN

The present invention provides an improved and commercially viable process for preparation of eprosartan and its pharmaceutically acceptable acid addition salts thereof in high purity and in high yield. Thus, for example, methyl 4-[[2-butyl-5-formyl-1 H-i

SUBSTITUTED-5-METHYLIDENE HYDANTOINS WITH AT1 RECEPTOR ANTAGONIST PROPERTIES

Substituted 1-benzylimidazole-5-methylidene hydantoins are disclosed as well as methods of preparing them, pharmaceutical compositions containing them, and method of using them. Intermediates useful in the preparation of the compounds of the invention are also disclosed and synthetic methods for preparing the novel intermediates. The compounds are useful as antagonists of angiotensin II and thus are useful in the control of hypertension, hyperaldosteronism, congestive heart failure, surgically induced vascular smooth muscle proliferation, and glaucoma.